Monte Rosa Therapeutics Announces Leadership Team Promotions
30 Mai 2024 - 1:00PM
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage
biotechnology company developing novel molecular glue degrader
(MGD)-based medicines, today announced three leadership team
promotions effective immediately: Sharon Townson, Ph.D., to Chief
Scientific Officer; Phil Nickson, Ph.D., J.D., to Chief Business
and Legal Officer; and Jennifer Champoux to Chief Operating
Officer.
“I am very pleased to announce the well-deserved promotions of
Sharon, Phil and Jennifer to expanded roles on our leadership
team,” said Markus Warmuth, M.D., Chief Executive Officer of Monte
Rosa Therapeutics. “Each has played a critical role in advancing
our pipeline programs, enhancing our QuEEN™ drug discovery engine,
developing relationships with premier biopharma companies, and
building an outstanding organization. I look forward to continued
work and collaboration with this talented group as we advance our
pipeline programs targeting cancers and immune-related diseases and
further leverage the potential of our AI/ML-driven discovery
engine.”
Sharon Townson, Ph.D., promoted to Chief
Scientific Officer, joined Monte Rosa as Chief Technology Officer
and brings expertise in molecular glues and targeted protein
degradation technology platforms. She joined the Company from
Kymera Therapeutics, where she served as Executive Director of
Platform Biology. Previously, she was on the leadership team of
Warp Drive Bio and was responsible for developing their novel
molecular glue approach to target KRAS. Sharon began her career at
Pfizer as a structural biologist and holds a Ph.D. in structural
biology and biochemistry from the University of Manchester
Institute of Technology.
Phil Nickson, Ph.D., J.D., promoted to Chief
Business and Legal Officer, joined the Company as General Counsel
and has provided general legal support, including work on
intellectual property matters and external business transactions.
Phil joined Monte Rosa with over 15 years of life sciences legal
experience. Previously, he was with Momenta Pharmaceuticals for
over 10 years, through the company’s acquisition by Johnson and
Johnson. Phil began his legal career with Fish and Richardson in
Boston. He holds a J.D. from Suffolk University and a Ph.D. from
the University of Manchester.
Jennifer Champoux, promoted to Chief Operating
Officer, joined Monte Rosa as Vice President of Operations, leading
overall corporate operations and Human Resources. Jen brings over
15 years of diverse operations experience, including site
operations, strategic planning, finance, communications, and
culture and employee engagement. Previously, she was with H3
Biomedicine, leading operations, communications, and finance
operations teams. Earlier, Jen was with Novartis Institutes for
Biomedical Research, leading operations for the Discovery Chemistry
group in Cambridge. She previously worked in various roles at Merck
and Array BioPharma. Jen holds an M.S. in chemistry from Indiana
University.
About Monte RosaMonte Rosa Therapeutics is a
clinical-stage biotechnology company developing highly selective
molecular glue degrader (MGD) medicines for patients living with
serious diseases in the areas of oncology, autoimmune and
inflammatory diseases, and more. MGDs are small molecule protein
degraders that have the potential to treat many diseases that other
modalities, including other degraders, cannot. Monte Rosa’s QuEEN™
(Quantitative and Engineered Elimination of Neosubstrates)
discovery engine combines AI-guided chemistry, diverse chemical
libraries, structural biology and proteomics to identify degradable
protein targets and rationally design MGDs with unprecedented
selectivity. The QuEEN discovery engine enables access to a
wide-ranging and differentiated target space of well-validated
biology across multiple therapeutic areas. Monte Rosa has developed
the industry’s leading pipeline of MGDs, which spans oncology,
autoimmune and inflammatory disease and beyond, and has a strategic
collaboration with Roche to discover and develop MGDs against
targets in cancer and neurological diseases previously considered
impossible to drug. For more information, visit
www.monterosatx.com.
InvestorsAndrew
Funderburkir@monterosatx.com
MediaCory Tromblee, Scient
PRmedia@monterosatx.com
Monte Rosa Therapeutics (NASDAQ:GLUE)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Monte Rosa Therapeutics (NASDAQ:GLUE)
Historical Stock Chart
Von Jun 2023 bis Jun 2024